The IQVIA Institute’s latest report identifies a biosimilar void. Despite their proven value, biosimilars are facing barriers at every turn. If nothing changes, patients and the healthcare system will pay the price.
Join Us February 3–5 for AAM’s Annual Meeting, Access! 2025
Access! 2025 will bring together policymakers, influential speakers and industry leaders to chart the future of generic and biosimilar medicines. Discussions center around the business, breakthroughs and politics that shape our industry. Register now to attend and learn what the future of our industry holds.
U.S. Generic & Biosimilar Medicines Savings Report
Representing 90% of prescriptions filled but only 13% of spending, generics and biosimilars are essential to America’s patients and the U.S. healthcare system. The 2024 U.S. Generic & Biosimilar Medicines Savings Report shows savings will continue to grow—with $445 billion saved in 2023, alone.
Press Releases
What’s New
Approved Biosimilars in the U.S.
>90
Biosimilars Currently in Development
2.7B
Days of Patient Therapy with Biosimilars
Incremental Days of Biosimilar Therapy
